B. Salles

发表

Long term outcome of patients with hairy cell leukemia treated with pentostatin

G. Salles, B. Coiffier, M. Blanc, 1999, Cancer.

Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years.

J. Blay, B. Coiffier, H. Tilly, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

D. Swinkels, A. Stamatoullas, C. Craddock, 2020, Leukemia.

Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants.

G. Salles, M. Fulham, H. Tilly, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia

G. Flandrin, H. Mossafa, V. Eclache, 2004, Leukemia.

Treatment of poor prognosis Burkitt's lymphoma in adults with the Société Française d'Oncologie Pédiatrique LMB Protocol--a study of the Federation Nationale des Centres de Lutte Contre le Cancer (FNLCC).

P. Colombat, T. Philip, C. Carrie, 1992, European journal of cancer.

Bone marrow histological patterns can predict survival of patients with grade 1 or 2 follicular lymphoma: a study from the Groupe d‘Etude des Lymphomes Folliculaires

L. Xerri, N. Brousse, É. Lepage, 2004, British journal of haematology.

Use of the monoclonal antibody anti-human epidermal growth factor receptor 2 (anti-HER2), trastuzumab, in the treatment of metastatic breast cancer: a cost-effectiveness analysis.

T. Bachelot, C. Colin, V. Trillet-lenoir, 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).

Late autologous transplantation in chronic myelogenous leukemia with peripheral blood progenitor cells mobilized by G-CSF and interferon-α

C. Vigouroux, C. Dumontet, X. Thomas, 2000, Leukemia.

Preferential splenic CD8(+) T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia.

B. Bonnotte, C. Ferrand, P. Saas, 2013, Blood.

Der(16)t(l;16)(qll;qll) in myelodysplastic syndromes: a new non‐random abnormality characterized by cytogenic and fluorescence in situ hybridization studies

E. Solary, N. Dastugue, F. Mugneret, 1995, British journal of haematology.

Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first‐line therapy for triple‐negative, metastatic, or locally advanced breast cancer: Results from the GINECO A‐TaXel phase 2 study

P. Follana, R. Largillier, J. Ferrero, 2016, Cancer.

Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.

F. Jardin, P. Gaulard, B. Coiffier, 2011, The Lancet. Oncology.

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

B. Pégourié, O. Decaux, P. Moreau, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bendamustine and rituximab in elderly patients with low‐tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study

R. Bouabdallah, L. Xerri, P. Feugier, 2018, British journal of haematology.

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.

Phase II study of PEG-Intron in combination with chemotherapy for the treatment of first line patients with follicular lymphoma who need to be treated.

P. Feugier, C. Haioun, F. Bauduer, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study

T. Bachelot, Claude D Martin, D. Pérol, 2008, Breast Cancer Research and Treatment.

Use of the Monoclonal Antibody Anti-HER2 Trastuzumab in the Treatment of Metastatic Breast Cancer: A Cost-Effectiveness Analysis

T. Bachelot, C. Colin, J. Jacquin, 2008, American journal of clinical oncology.